Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-09Clinical Trial Update: Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast Cancer [Phase 2]
A Phase 2 clinical trial evaluating peritumoral and periganglionic infiltration of levobupivacaine before conservative surgery in triple-neg…
-
CLINICAL_TRIALS research · 2026-03-09Clinical Trial Update: Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy [NA]
A multicenter MD Anderson trial investigates eliminating breast cancer surgery or radiotherapy in exceptional responders to neoadjuvant syst…
-
CLINICAL_TRIALS research · 2026-03-09Clinical Trial Update: Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer [Phase 2]
Phase 2 trial investigating neoadjuvant toripalimab with stereotactic body radiotherapy for chemo-resistant triple-negative breast cancer, c…
-
CLINICAL_TRIALS trial_result · 2026-03-05Clinical Trial Update: Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer [Phase 2]
Phase 2 trial results update evaluating estradiol for ER beta–positive, triple-negative breast cancer in locally advanced or metastatic dise…
-
CLINICAL_TRIALS withdrawal · 2026-03-05Clinical Trial Update: IL-1 Inhibition in Early TNBC [Phase 2]
A Phase 2 trial evaluating IL-1 inhibition in early-stage triple-negative breast cancer has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-03-05Clinical Trial Update: Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer [NA]
The study evaluating circulating tumor DNA–based minimal residual disease detection in early-stage breast cancer is currently suspended.
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
A study led by Tempus AI is evaluating minimal residual disease in breast cancer by longitudinal ctDNA profiling to track disease status acr…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer [Phase 2]
An open-label, single-center, single-arm Phase 2 trial assessing neoadjuvant pembrolizumab in combination with carboplatin and paclitaxel fo…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Microbiome Immunotherapy Neoadjuvant Assessment
The University College Cork-sponsored trial is evaluating microbiome-based immunotherapy as neoadjuvant treatment for triple-negative breast…
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: First in Human Study of TUB-030 in Patients With Advanced Solid Tumors [Phase 1, Phase 2]
First-in-human study of TUB-030 is underway in patients with advanced solid tumors, including head and neck squamous cell carcinoma, small c…
-
CLINICAL_TRIALS trial_result · 2026-03-03Clinical Trial Update: Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating preoperative chemotherapy with pembrolizumab and low or high dose radiation in node-positive, triple-negat…
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer [Phase 2]
A Phase 2 clinical trial is evaluating QL1706 in combination with chemotherapy as neoadjuvant therapy for triple-negative breast cancer and …
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation [Phase 2]
A Phase II, single-arm trial evaluating the efficacy and safety of Inavolisib in combination with Eribulin in pretreated advanced triple-neg…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease [Phase 2]
A Phase 2 clinical trial is evaluating whether adding stereotactic body radiotherapy to standard of care improves outcomes for patients with…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC [Phase 2]
Phase 2 clinical trial update on sacituzumab govitecan with or without pembrolizumab for metastatic triple-negative breast cancer, currently…
-
CLINICAL_TRIALS trial_result · 2026-02-25Clinical Trial Update: Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy [Phase 2]
A Phase 2 trial evaluating the safety and preliminary effectiveness of BNT327 in combination with chemotherapy for locally advanced, triple-…
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer [Phase 1]
Phase 1 safety study of a MELK inhibitor for advanced breast cancer including triple-negative breast cancer is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-02-25Clinical Trial Update: PRO1107 in Patients With Advanced Solid Tumors [Phase 1, Phase 2]
The Phase 1/2 PRO1107 trial in advanced solid tumors, including endometrial and ovarian cancers, has been terminated.
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer [Phase 2]
Phase 2 neoadjuvant trial evaluating posaconazole plus PD-1 inhibitors and chemotherapy versus PD-1 inhibitors and chemotherapy in triple-ne…
-
CLINICAL_TRIALS other · 2026-02-25Clinical Trial Update: A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors. [Phase 1]
Phase 1 multicenter imaging trial update for LNTH-2403 in locally advanced or metastatic solid tumors; currently NOT_YET_RECRUITING.
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer [Phase 1]
This clinical trial update announces the first-in-human, Phase 1 study of ATX-295, an oral inhibitor of KIF18A, in patients with advanced or…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer [Phase 1]
PQ203 from ProteinQure Inc. is in a Phase 1 trial for advanced malignant tumors, including triple-negative breast cancer, and recruitment is…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating pembrolizumab with paclitaxel, with or without bevacizumab, for recurrent triple-negative breast cancer; r…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer [Phase 1, Phase 2]
A phase 1/2 clinical trial investigating a personalized neoantigen-targeting cancer vaccine (NECVAX-NEO1) for neoadjuvant treatment in tripl…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI) [EARLY_Phase 1]
A Phase 1 trial at the University of Alabama at Birmingham is exploring PET/MRI imaging to monitor response to immunotherapy in patients wit…